Your browser doesn't support javascript.
loading
Macrophage migration inhibitory factor promotes tumor aggressiveness of esophageal squamous cell carcinoma via activation of Akt and inactivation of GSK3ß.
Liu, Rui-Min; Sun, Dan-Ni; Jiao, Ye-Lin; Wang, Pan; Zhang, Juan; Wang, Ming; Ma, Jin; Sun, Man; Gu, Bian-Li; Chen, Pan; Liu, Ke; Ma, Heng; Gao, She-Gan; Ma, Yuan-Fang; Qi, Yi-Jun.
Afiliación
  • Liu RM; Joint National Laboratory for Antibody Drug Engineering, Medical College of Henan University, Kaifeng, Henan, 475004, PR China.
  • Sun DN; Joint National Laboratory for Antibody Drug Engineering, Medical College of Henan University, Kaifeng, Henan, 475004, PR China.
  • Jiao YL; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China.
  • Wang P; First Teaching Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, PR China.
  • Zhang J; Joint National Laboratory for Antibody Drug Engineering, Medical College of Henan University, Kaifeng, Henan, 475004, PR China.
  • Wang M; Joint National Laboratory for Antibody Drug Engineering, Medical College of Henan University, Kaifeng, Henan, 475004, PR China.
  • Ma J; Joint National Laboratory for Antibody Drug Engineering, Medical College of Henan University, Kaifeng, Henan, 475004, PR China.
  • Sun M; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China.
  • Gu BL; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China.
  • Chen P; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China.
  • Liu K; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China.
  • Ma H; Respiratory Department, Xinmi Hospital of Traditional Chinese Medicine, Xinmi, 452370, PR China.
  • Gao SG; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China.
  • Ma YF; Joint National Laboratory for Antibody Drug Engineering, Medical College of Henan University, Kaifeng, Henan, 475004, PR China. Electronic address: mayf@henu.edu.cn.
  • Qi YJ; Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, PR China. Electronic address: qiyijun@hotmail.com.
Cancer Lett ; 412: 289-296, 2018 01 01.
Article en En | MEDLINE | ID: mdl-29079416
The pleiotropic pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF), represents an important link between chronic inflammation and tumorigenesis. Although accumulating evidence demonstrates that MIF overexpression is implicated in the development and progression of multiple cancers, including esophageal squamous cell carcinoma (ESCC), the molecular mechanisms underlying its tumor-promoting roles in ESCC remain unclear. In the present study, we observed that MIF is overexpressed in ESCC and correlated significantly with lymph node metastasis, advanced clinical stage, and poor survival of ESCC. MIF knockdown attenuated the proliferation, migration, and invasion of ESCC cells in vitro and in vivo. Moreover, blockage of MIF expression decreased the activation of the Akt, MEK/ERK, and NF-κB pathways and enhanced sensitivity to apoptosis. Meanwhile, repression of MIF expression resulted in activation of glycogen synthase kinase 3 beta (GSK3ß) and subsequent decrease of active ß-catenin, as well as its downstream targets including cyclin D1, matrix metalloproteinase (MMP)-7, c-myc, and c-Jun. Collectively, our results provided mechanistic insights into the tumor-promoting role of MIF in ESCC, and suggested that MIF represents a potential therapeutic target for treatment of ESCC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Factores Inhibidores de la Migración de Macrófagos / Proteínas Proto-Oncogénicas c-akt / Glucógeno Sintasa Quinasa 3 beta Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Lett Año: 2018 Tipo del documento: Article Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Factores Inhibidores de la Migración de Macrófagos / Proteínas Proto-Oncogénicas c-akt / Glucógeno Sintasa Quinasa 3 beta Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Lett Año: 2018 Tipo del documento: Article Pais de publicación: Irlanda